US OptionsDetailed Quotes
BDTX240816C7500
- 0.30
- +0.10+50.00%
15min DelayTrading Jul 23 10:01 ET
0.30High0.30Low
0.30Open0.20Pre Close20 Volume30 Open Interest7.50Strike Price600.00Turnover96.71%IV24.80%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.2678Delta0.2117Gamma27.78Leverage Ratio-0.0107Theta0.0010Rho7.44Eff Leverage0.0053Vega
Black Diamond Therapeutics Stock Discussion
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology medicine company focusing on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Their main product candidate, BDTX-1535, is designed to treat brain-penetrant epidermal growth factor receptor (EGFR) mutations, notably in non-small cell lung cancer (NSCLC) and gli...
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics presented promising clinical data on its lead candidate BDTX-1535 at the 2024 ASCO Annual Meeting. The Phase 1 dose escalation trial in recurrent glioblastoma (GBM) patients showed a favorable safety profile and encouraging anti-tumor activity, with sev...
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
No comment yet